Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Scott A. Reines"'
Autor:
Jordan E. Norris, Elizabeth M. Berry-Kravis, Mark D. Harnett, Scott A. Reines, Melody A. Reese, Abigail H. Outterson, Claire Michalak, Jeremiah Furman, Mark E. Gurney, Lauren E. Ethridge
Publikováno v:
Molecular Autism, Vol 15, Iss 1, Pp 1-6 (2024)
Abstract Fragile X syndrome (FXS) is a rare neurodevelopmental disorder caused by a CGG repeat expansion ≥ 200 repeats in 5’ untranslated region of the FMR1 gene, leading to intellectual disability and cognitive difficulties, including in the dom
Externí odkaz:
https://doaj.org/article/c3d257b9fa424b7f95d4a3eeaa327d8e
Publikováno v:
Substance Abuse: Research and Treatment, Vol 14 (2020)
Objective: To analyze the rates of misuse - that is, use in any way not directed by a doctor - of products containing oral tramadol, a Schedule IV opioid, from the National Survey of Drug Use and Health (NSDUH), as compared to comparator Schedule II
Externí odkaz:
https://doaj.org/article/b3875a1249914dc9b6ea11e700f9eace
Autor:
Melody A Reese, Lauren E. Ethridge, Abigail H Outterson, Claire Michalak, Jeremiah Furman, Mark Harnett, Mark E Gurney, Elizabeth Berry-Kravis, Scott A Reines
Publikováno v:
Nature Medicine. 27:862-870
The goal of this study was to determine whether a phosphodiesterase-4D (PDE4D) allosteric inhibitor (BPN14770) would improve cognitive function and behavioral outcomes in patients with fragile X syndrome (FXS). This phase 2 trial was a 24-week random
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c083ca5e5b6dda5c48c1dc091556aaae
https://doi.org/10.1038/s41591-021-01321-w
https://doi.org/10.1038/s41591-021-01321-w
Autor:
Neil Singla, Scott A Reines, David A. Leiman, Mark Harnett, Michael Ryan, Lucy Lu, Harold S. Minkowitz
Publikováno v:
Journal of Pain Research
Purpose There is a need to reduce exposure to Schedule II opioids in the United States (US) due to the ongoing opioid epidemic. Schedule II opioids have higher potential for abuse and misuse than Schedule IV opioids. This Phase 3, multicenter, single
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b0ed6d3e5d71a14fd49ed32129c7dba
https://doi.org/10.2147/jpr.s251175
https://doi.org/10.2147/jpr.s251175
Autor:
Mark Harnett, Michael Ryan, Harold S. Minkowitz, Daneshvari Solanki, Hernan Salazar, Neil Singla, Lucy Lu, David A. Leiman, Scott A Reines
Publikováno v:
Drugs in R&D, Vol 20, Iss 3, Pp 225-236 (2020)
Drugs in R&D
Drugs in R&D
Background and Objective Oral tramadol, an atypical opioid approved in the United States (US) since 1995 and a Schedule IV controlled substance, has less abuse liability compared to Schedule II conventional opioids. Intravenous (IV) tramadol is not a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01de97d4be775d2d67bf75e7a97eb08c
https://doaj.org/article/c56bd93c3d8c485392b8778f0109b340
https://doaj.org/article/c56bd93c3d8c485392b8778f0109b340
Autor:
Elizabeth M, Berry-Kravis, Mark D, Harnett, Scott A, Reines, Melody A, Reese, Lauren E, Ethridge, Abigail H, Outterson, Claire, Michalak, Jeremiah, Furman, Mark E, Gurney
Publikováno v:
Nature medicine. 27(5)
The goal of this study was to determine whether a phosphodiesterase-4D (PDE4D) allosteric inhibitor (BPN14770) would improve cognitive function and behavioral outcomes in patients with fragile X syndrome (FXS). This phase 2 trial was a 24-week random
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::51a8ac4b73426063219fd6dd778fe1c0
https://pubmed.ncbi.nlm.nih.gov/33927413
https://pubmed.ncbi.nlm.nih.gov/33927413
Publikováno v:
Journal of opioid management. 16(4)
Tramadol is a centrally acting dual-mechanism (opioid and monoamine reuptake inhibition) analgesic that has been noted to have a lower risk of abuse compared to conventional opioids such as morphine. Oral tramadol has been approved in the United Stat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51979c0319113595ba00fa4089883b78
https://pubmed.ncbi.nlm.nih.gov/32885838
https://pubmed.ncbi.nlm.nih.gov/32885838
Publikováno v:
Clinical Pharmacology in Drug Development
Tramadol is a dual‐mechanism (opiate and monoamine reuptake inhibition) analgesic. Intravenous (IV) tramadol has been widely prescribed outside the United States. However, there have not been studies comparing the pharmacokinetics (PK) of IV dosing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4a202ef6cd0d3ca209507504d9d0ade
https://pubmed.ncbi.nlm.nih.gov/31610100
https://pubmed.ncbi.nlm.nih.gov/31610100
Autor:
Richard Hargreaves, Armin Szegedi, Christopher Lines, Scott A. Reines, William A. Ball, Duane B. Snavely
Publikováno v:
Human Psychopharmacology: Clinical and Experimental. 29:568-577
Objective Aprepitant is a neurokinin 1 receptor antagonist approved for prevention of chemotherapy-induced and post-operative nausea and vomiting. Early studies demonstrated promising antidepressant activity as monotherapy, although this was unsuppor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa4298c658e6e8988ccab8b19cacab5b
https://doi.org/10.1002/hup.2444
https://doi.org/10.1002/hup.2444
Autor:
Richard Hargreaves, Scott A. Reines, Paulette Ceesay, Jarmo Hietala, Christopher Lines, Robert C. Alexander, David Michelson
Publikováno v:
International Journal of Neuropsychopharmacology. 16(1):1-11
Preclinical studies suggest that substance P acting at neurokinin 1 (NK1) receptors may be involved in stress responses and NK1 receptor antagonists show activity in tests of anxiety. These data raise the possibility that NK1 receptor antagonists cou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01201264df3128b21d69d7fb4c5bf5e4
https://doi.org/10.1017/S1461145712000065
https://doi.org/10.1017/S1461145712000065